International Journal of Endocrinology and Metabolism

Published by: Kowsar

An Extracellular Matrix Molecule, Secreted by the Epithelial-Mesenchymal Transition is Associated With Lymph Node Metastasis of Thyroid Papillary Carcinoma

Hiroshi Takeyama 1 , * , Yoshinobu Manome 2 , Kouki Fujioka 2 , Isao Tabei 1 , Hiroko Nogi , Yasuo Toriumi 1 , Kumiko Kato 1 , Makiko Kamio 1 , Yoshimi Imawari 1 , Satoki Kinoshita 1 , Naoshi Akiba 1 , Ken Uchida 1 and Toshiaki Morikawa 1
Authors Information
1 Department of Surgery, Jikei University School of Medicine, Tokyo, Japan
2 Department of Molecular Cell Biology, Jikei University School of Medicine, Tokyo, Japan
Article information
  • International Journal of Endocrinology and Metabolism: January 01, 2014, 12 (1); e10748
  • Published Online: January 1, 2014
  • Article Type: Research Article
  • Received: February 19, 2013
  • Revised: September 18, 2013
  • Accepted: September 21, 2013
  • DOI: 10.5812/ijem.10748

To Cite: Takeyama H, Manome Y, Fujioka K, Tabei I, Nogi H, et al. An Extracellular Matrix Molecule, Secreted by the Epithelial-Mesenchymal Transition is Associated With Lymph Node Metastasis of Thyroid Papillary Carcinoma, Int J Endocrinol Metab. 2014 ; 12(1):e10748. doi: 10.5812/ijem.10748.

Copyright © 2014, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Chen H, Nicol TL, Udelsman R. Follicular lesions of the thyroid. Does frozen section evaluation alter operative management? Ann Surg. 1995; 222(1): 101-6[PubMed]
  • 2. McHenry CR, Thomas SR, Slusarczyk SJ, Khiyami A. Follicular or Hurthle cell neoplasm of the thyroid: can clinical factors be used to predict carcinoma and determine extent of thyroidectomy? Surgery. 1999; 126(4): 798-802[PubMed]
  • 3. Greaves TS, Olvera M, Florentine BD, Raza AS, Cobb CJ, Tsao-Wei DD, et al. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer. 2000; 90(6): 335-41[PubMed]
  • 4. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998; 338(5): 297-306[DOI][PubMed]
  • 5. Chang HY, Lin JD, Chou SC, Chao TC, Hsueh C. Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas. Jpn J Clin Oncol. 2006; 36(11): 688-93[DOI][PubMed]
  • 6. Young RL, Mazzaferri EL, Rahe AJ, Dorfman SG. Pure follicular thyroid carcinoma: impact of therapy in 214 patients. J Nucl Med. 1980; 21(8): 733-7[PubMed]
  • 7. Takano T, Matsuzuka F, Sumizaki H, Kuma K, Amino N. Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Cancer Res. 1997; 57(17): 3792-7[PubMed]
  • 8. Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P, et al. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid. 2003; 13(8): 765-70[DOI][PubMed]
  • 9. Hesse E, Musholt PB, Potter E, Petrich T, Wehmeier M, von Wasielewski R, et al. Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma. Br J Cancer. 2005; 93(5): 565-70[DOI][PubMed]
  • 10. Takeyama H, Hosoya T, Sakurai K, Mori Y, Watanabe M, Kisaki H, et al. Production of a novel monoclonal antibody, JT-95, which can detect antigen of thyroid carcinoma. Cancer Res. 1996; 56(8): 1817-22[PubMed]
  • 11. Kimura N, Kurokawa K, Yamamoto K, Narimatsu H, Kimura H, Hosoya T, et al. Molecular identification of the antigens recognized by monoclonal antibody JT95 specific for thyroid carcinomas. Biochem Biophys Res Commun. 1998; 251(2): 449-53[PubMed]
  • 12. Ryu Shinso, Jimi Shiro, Takebayashi Shigeo. Thyroid carcinoma distinctively expresses intracellular fibronectin in vivo. Cancer Lett. 1997; 121(2): 189-193
  • 13. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005; 18(1): 48-57[DOI][PubMed]
  • 14. Matsuura H, Takio K, Titani K, Greene T, Levery SB, Salyan ME, et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J Biol Chem. 1988; 263(7): 3314-22[PubMed]
  • 15. Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc Natl Acad Sci U S A. 1985; 82(19): 6517-21[PubMed]
  • 16. Loridon-Rosa B, Vielh P, Matsuura H, Clausen H, Cuadrado C, Burtin P. Distribution of oncofetal fibronectin in human mammary tumors: immunofluorescence study on histological sections. Cancer Res. 1990; 50(5): 1608-12[PubMed]
  • 17. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7(2): 131-42[DOI][PubMed]
  • 18. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H, et al. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res. 2008; 68(13): 5104-12[DOI][PubMed]
  • 19. Arima Y, Hayashi H, Sasaki M, Hosonaga M, Goto TM, Chiyoda T, et al. Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer. J Biol Chem. 2012; 287(11): 7896-906[DOI][PubMed]
  • 20. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5): 891-906[DOI][PubMed]
  • 21. De Amicis F, Perri A, Vizza D, Russo A, Panno ML, Bonofiglio D, et al. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013; 228(10): 2054-62[DOI][PubMed]
  • 22. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4): 704-15[DOI][PubMed]
  • 23. Hemler ME. VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol. 1990; 8: 365-400[DOI][PubMed]
  • 24. Guan JL, Hynes RO. Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell. 1990; 60(1): 53-61[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments